Sitemap > News > Neurodegenerative & Neuroelectrophysiological Disorders
- Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
- BioMS Initiates Enrollment In Pivotal U.S. Phase III MS Trial
- Teva And Active Biotech To Initiate Pivotal Phase III Trial Program Of Oral Laquinimod For Relapsing Multiple Sclerosis
- Opexa Presents Tovaxin Research at Federation of Clinical Immunology Societies Annual Meeting
- Pipex Pharmaceuticals’ Oral TRIMESTA Initiates Enrollment of Phase II/III Clinical Trial for Multiple Sclerosis.
- CoMentis Receives FDA Clearance to Begin Human Clinical Trials
- Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED™)
- Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin™ for Multiple Sclerosis
- Tramiprosate (ALZHEMED) North American Phase III clinical trial progress update
- CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
- Alseres Pharmaceuticals Announces FDA Clearance to Increase Dose Level in Cethrin(R) Phase I/IIa Clinical Trial for Acute Spinal Cord Injury at U.S. Sites
- UCB and Biogen Idec’s oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis
- Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US
- Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial
- FDA Approves Demipulse And Demipulse Duo Generators
- Patient Enrollment on Target in National Institutes of Health Phase III Parkinson’s Disease Trial
- Avicena to Proceed to Confirmatory Phase III
- Cortex to Resume Clinical Trial with AMPAKINE CX717 in Alzheimer-PET Scan Study After FDA Approves Protocol with Higher Doses of Drug
- Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Alzheimer’s Disease
- Neurochem granted fast track designation from U.S. FDA for tramiprosate (ALZHEMED)
- BioMS Relapsing-Remitting MS Trial Receives Positive Review From Data Safety Monitoring Board
- Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
- Targacept Initiates Phase I Clinical Trial of TC-5619
- Lexicon Drug Candidate For Cognitive Disorders Successfully Completes Phase 1 Clinical Trial
- Medivation Announces Treatment of First Patient in Phase 2 Trial of Dimebon in Huntington's Disease
- Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
- Lexicon Drug Candidate For Cognitive Disorders Successfully Completes Phase 1 Clinical Trial
- Prana today announced an update on its Phase IIa clinical trial of PBT2 in patients with Alzheimer’s disease.
- Stem Cell Therapeutics Opens Second Clinical Trial Site for Its Lead Stroke Program
- Sirtris Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of SRT501 in MELAS
- Neurochem announces results from tramiprosate (ALZHEMED™) North American Phase III clinical trial
- Ketasyn Improves Memory in Age-Associated Memory Impairment Study
- Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
- Transition Therapeutics Announces Completion of Phase I Clinical Studies with Alzheimer\'s Disease Drug Candidate ELND-005/AZD-103
- Avigen Initiates European Multi-Center AV650 Phase II Spasticity Trial in Patients with Multiple Sclerosis
- Icagen Announces Initiation of Phase I Study of ICA-105665, a Novel Compound for the Treatment of Epilepsy
- OVATION FURTHER ADVANCES DEVELOPMENT PIPELINE WITH NEW PHASE III EPILEPSY STUDY
- ATL1102 MS Phase IIa Trial Update
- Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin® for Treatment of Multiple Sclerosis
- SYGNIS’ AX200 shows efficacy in stroke patients – Phase IIa results exceed expectations
- Neuren completes moderate TBI Phase 1b safety trial of NNZ-2566
- Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer\'s disease
- CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
- Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704
- Prana Completes Enrollment in Phase IIa Trial of PBT2 in Alzheimer’s Disease Patients
- Alseres Pharmaceuticals\' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
- Alseres Pharmaceuticals\' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
- Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich\'s Ataxia and Provides Details on Study Design
- Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich\'s Ataxia and Provides Details on Study Design
- NeuroSearch files Clinical Trial Application for the initiation of a clinical Phase III programme with ACR16 in Huntington’s disease in Europe
- Trophos starts Phase Ib Clinical Trial of TRO19622 in Spinal Muscular Atrophy
- Allon Therapeutics completes enrolment for Phase II Alzheimer’s trial
- Imaging Agent from Avid Radiopharmaceuticals to be Licensed by Bayer Schering Pharma for Early Detection of Alzheimer\'s Disease
- AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
- Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
- Sirtris Pharmaceuticals\' Oral Drug Candidate SRT501 Shown To Be Neuroprotective: Implications for SIRT1 Activation in Neurodegenerative Eye Disorders
- BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
- Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer\'s Disease
- Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
- Copaxone® Significantly Decreases Disease Activity In Patients Who Switched From Interferon Beta (Ifnb) Due To Development Of Neutralizing Antibodies (Nabs)
- EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
- Memory Pharmaceuticals Corp. Conference Call to Discuss Positive Phase 2a Results for MEM 3454 in Alzheimer\'s Disease
- Neuren completes moderate TBI Phase 1b safety trial of NNZ-2566
- Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis
- BioMS Relapsing-Remitting MS Trial Receives Positive Review From Data Safety Monitoring Board
- Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal
- BioMS Medical Achieves Enrollment Milestone in U.S. Phase III Multiple Sclerosis Trial
- Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson\'s Disease
- CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol
- Valeant Pharmaceuticals Completes Enrollment of Second Pivotal Phase 3 Trial for Epilepsy Drug Retigabine
- Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson\'s Disease
- Adult Stem Cell Product to be Tested in Stroke Trial
- Pipex Pharmaceuticals Files New Drug Application (NDA) with FDA
- First Patient Completes StemCells, Inc.’s Phase I Clinical Trial
- Acorda Therapeutics Completes Enrollment of Phase 3 Clinical Trial of Fampridine-SR
- UCB Announces Positive Phase III Trial Results for Keppra XR
- # Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
- Stem Cell Therapeutics Announces Receipt of No Objection Letter From Health Canada for Its Phase IIb Clinical Trial in Stroke
- Lexicon Initiates Phase 2A Trial of LX6171 Drug Candidate for Cognitive Disorders
- ANAVEX advances drug candidates for treatment of epilepsy
- AVANIR Enrolls First Patient in Confirmatory Phase III Trial of Zenvia(TM) in PBA
- Cyberkinetics Receives FDA Response Letter on Andara(TM) OFS(TM) System for Acute Spinal Cord Injury
- BioMS Phase III U.S. MS Trial Receives Positive Safety Review from Data Safety Monitoring Board
- Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson\'s Disease
- Neupro® Filed with the FDA for the Treatment of Advanced-Stage Parkinson\'s Disease
- Neurologix Gene Therapy Approach to Parkinson\'s Disease Granted Fast Track Designation From FDA
- Neurochem announces European opinion for Eprodisate (KIACTA) for the treatment of AA amyloidosis
- Nutra Pharma Announces Successful Completion of 6-Month Patient Crossover in AMN Clinical Trial
- NeuroSearch initiates clinical Phase I study with ACR343 as a potential new treatment for Parkinson’s disease
- Prana Completes Final Patient Dosing in Phase IIa Trial of PBT2 in Alzheimer\'s Disease Patients
- EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer\'s Disease; Statistically Significant Improvement in Cognitive Function Achieved Within Two Weeks
- Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
- AstraZeneca And Banner Alzheimer’s Institute Collaborate To Evaluate New Tool Targeting Alzheimer’s Disease
- CytRx Initiates Phase IIb Efficacy Clinical Trial with Arimoclomol for Treatment of ALS
- Allon Therapeutics completes dosing in Phase II clinical trial in Alzheimer\'s program
- EXONHIT GETS REGULATORY APPROVAL TO INITIATE A PHASE 2 CLINICAL TRIAL FOR EHT 0202 IN ALZHEIMER\'S DISEASE
- Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
- Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer\'s Disease
- Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer\'s Disease
- Pipex Pharmaceuticals Files New Drug Application (NDA) with FDA
- Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury.
- CoMentis Announces Proof-of-Activity-Data from its Phase I Study of Disease-Modifying Alzheimer’s
- amarin to commence phase ii trial with amr101 in age associated memory impairment
- Allon trial studies pharmacokinetics of Al-108 & AL-208
- amarin to commence phase ii trial with amr101 in age associated memory impairment
- FDA Approves TYSABRI® for the Treatment of Moderate-to-Severe Crohn\'s Disease
- EPIX Pharmaceuticals Announces Updated Results from Phase 2a Clinical Trial of PRX-03140 in Alzheimer\'s Disease
- Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug Rufinamide
- Northstar Neuroscience Announces Updated Timeline for EVEREST Pivotal Trial Data Analysis and Planned PMA Submission
- CytRx Provides Update on Phase IIb Arimoclomol Clinical Trial for ALS
- Neuronetrix and the University of Kentucky Test New Device to Screen for Alzheimer’s Disease
- Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
- Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer\'s Disease in Second Quarter of 2008
- IMPAX Receives FDA Non-Approvable Letter for Vadova(R); Company Considering Options
- Neuro-Hitech Reports Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer\'s Disease Patients
- MediciNova\'s MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
- Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
- Neurogen Announces R&D Update
- CytRx Receives FDA Correspondence Regarding Phase IIb Arimoclomol Clinical Trial in ALS
- VALEANT PHARMACEUTICALS REPORTS POSITIVE PHASE III RESULTS FOR RETIGABINE IN RESTORE 1
- Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
- Chelsea Therapeutics Receives Special Protocol Assessment for Pivotal Phase 3 Study of Droxidopa in Neurogenic Orthostatic Hypotension
- Prana Announces Success in Phase IIa Clinical Trial of PBT2 in Early Alzheimer\'s Disease
- Kyowa Hakko Receives Not Approvable Letter from FDA for Istradefylline (KW-6002)
- Allon\'s Phase II clinical trial shows statistically significant efficacy on human cognition and memory
- Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
- Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin for Treatment of Multiple Sclerosis
- XenoPort Announces Positive Results of a Phase 1 Clinical Trial of XP21279
- Avicena\'s HD-02 to Proceed to NIH Sponsored Phase III Huntington\'s Disease Trial
- Medivation\'s Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer\'s Disease Patients, Resulting in Reduced Caregiver Distress
- Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
- CytRx Submits Response to FDA Related to Clinical Program with Arimoclomol in ALS
- Neurologix Receives FDA Clearance to Initiate Phase 2 Trial in Parkinson\'s Disease Subjects
- Evotec\'s EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity during the Performance of Cognitive Tasks
- ATL1102 Phase IIa MS Trial Update
- Lilly Launches Its First Phase III Trial for Treatment of Alzheimer\'s Disease
- ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson\'s Disease Psychosis
- MediciNova Reports Clinical Results From Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
- Knopp Neurosciences Initiates Phase 2 Study of KNS-760704 in Amyotrophic Lateral Sclerosis
- Phase III MS Neuropathic Pain Trial Preliminary Results
- ThromboGenics announces that it has completed patient enrolment for its Phase II MITI IV study
- Synthetic Blood International, Inc. Announces Plans to File Protocol for Phase II-b Oxycyte Clinical Trial
- Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
- BioMS Medical’s Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review from Data Safety Monitoring Board
- EARLY TREATMENT WITH COPAXONE® SIGNIFICANTLY DELAYED PROGRESSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS
- ANP completes ATL1102 Phase IIa Multiple Sclerosis Trial
- Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer\'s Disease Announced
- Stem Cell Therapeutics Corp. Receives \"May Proceed\" From FDA for Its Phase IIb Clinical Stroke Trial and IND
- Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis
- MERCK SERONO ANNOUNCES INITIATION OF PHASE II CLINICAL TRIAL OF ATACICEPT IN RELAPSING MULTIPLE SCLEROSIS
- EPIX Pharmaceuticals Initiates Phase 2b Program in Alzheimer\'s Disease
- FDA Grants Priority Review of Gamunex as a Treatment for Neurological Disorder CIDP
- Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin® Clinical Trial in Acute Spinal Cord Injury
- VALEANT ANNOUNCES SUCCESFUL COMPLETION OF RETIGABINE PHASE III EPILEPSY PROGRAM VALIDATING NOVEL MECHANISM OF ACTION
- FDA Places Geron’s GRNOPC1 IND on Clinical Hold
